Crinetics Pharmaceuticals Inc.

134 articles about Crinetics Pharmaceuticals Inc.

• Crinetics Pharmaceuticals Provides Update on CRN04777 Program

  11/28/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI).

• Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

  11/22/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022.

• Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/14/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2022.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2022

  11/10/2022

  Crinetics Pharmaceuticals, Inc. announced that on November 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 200,000 shares of its common stock to four new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of AcromegalyTopline results for PATHFNDR-1 study expected in Q3 2023

  10/13/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of once-daily oral paltusotine in acromegaly patients.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 10, 2022

  10/10/2022

  Crinetics Pharmaceuticals, Inc. announced that on October 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 237,600 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

  10/6/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism (HI), which enables Crinetics to access the Innovative Licensing and Access Pathway (ILAP).

• Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

  10/3/2022

  Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 12, 2022

  9/12/2022

  Crinetics Pharmaceuticals, Inc. announced that on September 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 246,600 shares of its common stock to thirteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/8/2022

  Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

• New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

  9/6/2022

  Crinetics Pharmaceuticals announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, presented new data from the planned two-year interim analysis of the ACROBAT Advance open label extension study at the 35th Brazilian Congress of Endocrinology and Metabolism.

• New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

  9/2/2022

  Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, will be presenting data from a planned two-year interim analysis from the ACROBAT Advance open label extension (OLE) study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM) being held in São Paulo, Brazil from September 3-7, 2022.

• Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/12/2022

  Crinetics Pharmaceuticals today reported financial results for the second quarter ended June 30, 2022.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 10, 2022

  8/10/2022

  Crinetics Pharmaceuticals, Inc. announced that on August 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,100 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc.

• Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

  8/4/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review additional analyses from the preclinical and Phase 1 clinical studies of CRN04894 in an oral presentation at the 10th International Congress of Neuroendocrinology (ICN), being held August 7-10, 2022.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 12, 2022

  7/12/2022

  Crinetics Pharmaceuticals, Inc. announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,500 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 10, 2022

  6/10/2022

  Crinetics Pharmaceuticals, Inc. announced that on June 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 138,500 shares of its common stock to seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics Presents Clinical and Research Results at ENDO 2022CRN04894 Selected for Oral Presentation

  6/8/2022

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894 , the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting.

• Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

  6/7/2022

  Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022.

• Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

  5/25/2022

  Crinetics Pharmaceuticals, Inc. today announced positive results from the multiple-ascending dose (MAD) portion of a first-in-human Phase 1 clinical study of CRN04894